
Eli Lilly and Co. (NYSE:LLY) CEO Dave Ricks strongly criticized the United Kingdom's approach to drug pricing, describing it as "probably the worst country in Europe" for pharmaceutical prices.
He warned that patients may miss out on new medicines if conditions do not improve.